Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfathiourea is a short‐acting sulfonamide antibiotic belonging to the class of aminobenzenesulfonamides and thioureas. It acts as an antibacterial agent by inhibiting dihydropteroate synthase (EC 2.5.1.15), thereby interfering with folic acid synthesis in bacteria, which is essential for their growth and replication[1][2]. Sulfathiourea is functionally related to sulfanilamide and has been shown to be bactericidal when added early in bacterial culture growth, with particular efficacy against Gram-positive organisms such as haemolytic streptococci and staphylococci, though it is less effective than some other sulfonamides against most Gram-negative organisms except Shigella[3][5]. It has been marketed under the brand name Badional.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfathiourea.